Octagon Capital Advisors »

Rapt Therapeutics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2023-12-31 $7.3M 292k 24.85

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals (APLS)
Cymabay Therapeutics
Verona Pharma Sponsored Ads (VRNA)
Insmed Com Par $.01 (INSM)
Arcus Biosciences Incorporated (RCUS)
Bridgebio Pharma (BBIO)
Celldex Therapeutics Com New (CLDX)
Roivant Sciences SHS (ROIV)
Alpine Immune Sciences (ALPN)
Structure Therapeutics Sponsored Ads (GPCR)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
An2 Therapeutics (ANTX)
Miragen Therapeutics (VRDN)
Immunovant (IMVT)
Dyne Therapeutics (DYN)

View all positions for Octagon Capital Advisors

Top funds holding Rapt Therapeutics

T. Rowe Price Associates
Column Group
Perceptive Advisors
Vanguard Group
Dr. Jeffrey R. Jay, M.D.
Kingdon Capital Management
Samlyn Capital
Euclidean Capital
Dimensional Fund Advisors
Alphabet
Cormorant Asset Management
Millennium Management
Citadel Advisors
Braidwell
Redmile Group

View all funds holding Rapt Therapeutics